7/2023
Acquistion of celares GmBH
6/2022
Sale of the company to Medix Biochemica
5/2022
Sale of the company to Biosynth Carbosynth
2/2022
Aquisition of antibodies-online
2/2022
Acquisition of FlowMetric
1/2022
Sale of the company to Maravai LifeSciences
12/2021
Sale of the company to Element Materials Technology
11/2021
Sale of the company to Cytek Biosciences
10/2021
Sale of the company to Element Materials Technology
4/2021
Sale of the company to Vitruvian
7/2019
Sale of the company to Versiti
4/2019
Sale of the company to BioLife Solutions
10/2018
Sale of the company to PerkinElmer
9/2018
Sale of company to Thompson Street Capital Partners
2/2018
Sale of the company to LGC Limited
7/2017
Sale of the company to Thermo Fisher Scientific Inc.
6/2017
Sale of the company to Unchained Labs
6/2017
1/2017
Sale of the company to Takara Bio Inc.
11/2016
Sale of the company to Thermo Fisher Scientific Inc.
10/2016
Strategic acquisition of TriLink Biotechnologies
10/2016
Strategic acquisition of Cygnus
7/2016
Sale of the company to PerkinElmer
7/2016
Clarity Medical Systems has sold its RetCam Ophthalmic Imaging System business to Natus Medical
3/2016
Sale of the company to Lab Corporation of America
3/2016
Strategic equity investment in Vector Laboratories
7/2015
Sale of the company to OpGen, Inc.
9/2014
Sale of the iPS Cell Business Unit of Stemgent ReproCELL, Inc.
8/2014
Sale of miRInform Thyroid and Pancrease Test to PDI Inc. (now Interpace Diagnostics)
7/2014
Sale of company to StoneCalibre
3/2014
Equity investment and strategic collaboration with Brooks Automation, Inc.
2/2014
Sale of in-vivo preclinical services business to BIOQUAL, Inc.
8/2013
Sale of sequencing services business to BioReference Laboratories, Inc.
7/2013
Sale of the Life Science business of SDIX to OriGene Technologies, Inc.
4/2013
Sale of UVP LLC to Analytik Jena AG
12/2012
Sale of BioServices business to Precision Bioservices
10/2012
Sale of Food Safety and GMO businesses
to Romer Labs
9/2012
Sale of preclinical in-vivo imaging business to Bruker
3/2012
Exclusive placement agent for OpGen, Inc.
12/2011
BroadOak Partners provided financial advisory
services to Quanta Biosciences
9/2011
Non-exclusive license agreement with QIAGEN
9/2011
BroadOak retained to provide ongoing financial
advisory services
9/2010
SVT gains exclusive rights in China to ENMD-2076 through investment in EntreMed, Inc.
7/2010
Replacement and expansion of Cayman Chemical Company’s debt facilities
6/2010
Acquisition of Hyaluron, Inc.
4/2010
Acquisition of GlobalStem, Inc.
12/2009
Sale of in-vivo preclinical CRO services business to
Taconic Farms, Inc.
10/2009
Sale of Alpha Innotech Corp. to Cell Biosciences, Inc.
10/2009
Collaboration and license agreement with Novartis
8/2009
Sale of non-core assets to Intrexon Corporation
3/2009
Sale of Assay Designs, Inc. to Enzo Biochem, Inc.
10/2008
Sale of Semrock Inc. to IDEX Corp
4/2008
Acquisition of biodefense vaccines business from
Avecia Biologics Limited
6/2007
Sale of Fluorescent Detection Products Business
7/2006
Sale of In Vitro Technologies, Inc to Celsis International Plc
3/2006
Acquisition of sales and marketing rights to EpiPen in Canada from Allerex Laboratory
12/2005
Acquisition of Control Delivery Systems
10/2005
Sale of NovaScreen Biosciences to Caliper Life Sciences
10/2005
Merger with xantra
7/2001
Sale of Sybron Biochemical Division to Novozymes
5/2001
Sale of publicly traded medical device company to Gyrus Group
2/2001
Sale of Munich based medical device company to ResMed
Code for Load More button – Do Not Delete
We believe true success for our companies comes from supporting the management team first.
Robert Wicke
Operating Partner
With unmatched experience and expertise, we help life sciences companies achieve their goals.